200 related articles for article (PubMed ID: 27228223)
1. Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms.
Shi J; Wang X; Eyler RF; Liang Y; Liu L; Mueller BA; Zhu HJ
Basic Clin Pharmacol Toxicol; 2016 Dec; 119(6):555-561. PubMed ID: 27228223
[TBL] [Abstract][Full Text] [Related]
2. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender.
Shi J; Wang X; Nguyen JH; Bleske BE; Liang Y; Liu L; Zhu HJ
Biochem Pharmacol; 2016 Nov; 119():76-84. PubMed ID: 27614009
[TBL] [Abstract][Full Text] [Related]
3. Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants.
Zhu HJ; Markowitz JS
Drug Metab Dispos; 2009 Feb; 37(2):264-7. PubMed ID: 19022936
[TBL] [Abstract][Full Text] [Related]
4. CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors.
Wang X; Wang G; Shi J; Aa J; Comas R; Liang Y; Zhu HJ
Pharmacogenomics J; 2016 Jun; 16(3):220-30. PubMed ID: 26076923
[TBL] [Abstract][Full Text] [Related]
5. CES1P1 variant -816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril.
Zhu HJ; Langaee TY; Gong Y; Wang X; Pepine CJ; Cooper-DeHoff RM; Johnson JA; Markowitz JS
Eur J Clin Pharmacol; 2016 Jun; 72(6):681-7. PubMed ID: 26915813
[TBL] [Abstract][Full Text] [Related]
6. Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans.
Tarkiainen EK; Backman JT; Neuvonen M; Neuvonen PJ; Schwab M; Niemi M
Clin Pharmacol Ther; 2012 Jul; 92(1):68-71. PubMed ID: 22588607
[TBL] [Abstract][Full Text] [Related]
7. Effects of alcohol on human carboxylesterase drug metabolism.
Parker RB; Hu ZY; Meibohm B; Laizure SC
Clin Pharmacokinet; 2015 Jun; 54(6):627-38. PubMed ID: 25511794
[TBL] [Abstract][Full Text] [Related]
8. Physiologically based pharmacokinetic modeling of impaired carboxylesterase-1 activity: effects on oseltamivir disposition.
Hu ZY; Edginton AN; Laizure SC; Parker RB
Clin Pharmacokinet; 2014 Sep; 53(9):825-36. PubMed ID: 25103325
[TBL] [Abstract][Full Text] [Related]
9. Surge in expression of carboxylesterase 1 during the post-neonatal stage enables a rapid gain of the capacity to activate the anti-influenza prodrug oseltamivir.
Shi D; Yang D; Prinssen EP; Davies BE; Yan B
J Infect Dis; 2011 Apr; 203(7):937-42. PubMed ID: 21402544
[TBL] [Abstract][Full Text] [Related]
10. Effects of Genetic Variants on Carboxylesterase 1 Gene Expression, and Clopidogrel Pharmacokinetics and Antiplatelet Effects.
Neuvonen M; Tarkiainen EK; Tornio A; Hirvensalo P; Tapaninen T; Paile-Hyvärinen M; Itkonen MK; Holmberg MT; Kärjä V; Männistö VT; Neuvonen PJ; Pihlajamäki J; Backman JT; Niemi M
Basic Clin Pharmacol Toxicol; 2018 Mar; 122(3):341-345. PubMed ID: 28990360
[TBL] [Abstract][Full Text] [Related]
11. The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humans.
Oh J; Lee S; Lee H; Cho JY; Yoon SH; Jang IJ; Yu KS; Lim KS
PLoS One; 2017; 12(4):e0176320. PubMed ID: 28437488
[TBL] [Abstract][Full Text] [Related]
12. The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect.
Merali Z; Ross S; Paré G
Drug Metabol Drug Interact; 2014; 29(3):143-51. PubMed ID: 24988246
[TBL] [Abstract][Full Text] [Related]
13. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel.
Shi D; Yang J; Yang D; LeCluyse EL; Black C; You L; Akhlaghi F; Yan B
J Pharmacol Exp Ther; 2006 Dec; 319(3):1477-84. PubMed ID: 16966469
[TBL] [Abstract][Full Text] [Related]
14. Carboxylesterase 1 (CES1) genetic polymorphisms and oseltamivir activation.
Zhu HJ; Markowitz JS
Eur J Clin Pharmacol; 2013 Mar; 69(3):733-4. PubMed ID: 22847618
[No Abstract] [Full Text] [Related]
15. A simple allele-specific polymerase chain reaction method to detect the Gly143Glu polymorphism in the human carboxylesterase 1 gene: importance of genotyping for pharmacogenetic treatment.
Walter Soria N; Belaus A; Galván C; Ana Pasquali M; Velez P; Del Carmen Montes C; Beltramo DM
Genet Test Mol Biomarkers; 2010 Dec; 14(6):749-51. PubMed ID: 20858053
[TBL] [Abstract][Full Text] [Related]
16. Sacubitril Is Selectively Activated by Carboxylesterase 1 (CES1) in the Liver and the Activation Is Affected by CES1 Genetic Variation.
Shi J; Wang X; Nguyen J; Wu AH; Bleske BE; Zhu HJ
Drug Metab Dispos; 2016 Apr; 44(4):554-9. PubMed ID: 26817948
[TBL] [Abstract][Full Text] [Related]
17. Substrate-Competitive Activity-Based Profiling of Ester Prodrug Activating Enzymes.
Xu H; Majmudar JD; Davda D; Ghanakota P; Kim KH; Carlson HA; Showalter HD; Martin BR; Amidon GL
Mol Pharm; 2015 Sep; 12(9):3399-407. PubMed ID: 26262434
[TBL] [Abstract][Full Text] [Related]
18. Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation.
Zhu HJ; Wang X; Gawronski BE; Brinda BJ; Angiolillo DJ; Markowitz JS
J Pharmacol Exp Ther; 2013 Mar; 344(3):665-72. PubMed ID: 23275066
[TBL] [Abstract][Full Text] [Related]
19. Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin.
Yang D; Pearce RE; Wang X; Gaedigk R; Wan YJ; Yan B
Biochem Pharmacol; 2009 Jan; 77(2):238-47. PubMed ID: 18983829
[TBL] [Abstract][Full Text] [Related]
20. Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants.
Boberg M; Vrana M; Mehrotra A; Pearce RE; Gaedigk A; Bhatt DK; Leeder JS; Prasad B
Drug Metab Dispos; 2017 Feb; 45(2):216-223. PubMed ID: 27895113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
